Oculus Innovative Sciences, Inc. Announces Results From Anti-Inflammatory Study Using Microcyn(R) Technology

PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today announced that International Immunopharmacology has published results from a company-sponsored study evaluating the impact of the Microcyn® Technology, a super-oxidized oxychlorine compound, on degranulation and cytokine release in mast cells. A reprint of the study can be viewed online: http://www.oculusis.com/articles/mastcells.pdf.